AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) insider Lawrence G. Hamel sold 10,161 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $5.29, for a total value of $53,751.69. Following the transaction, the insider now owns 16,379 shares in the company, valued at approximately $86,644.91. The sale was disclosed in a document filed with the SEC, which is available through this link.

Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ ACRX) remained flat at $5.50 during mid-day trading on Tuesday. The company had a trading volume of 3,881,862 shares. AcelRx Pharmaceuticals, Inc. has a 52-week low of $1.95 and a 52-week high of $5.75. The stock’s market capitalization is $249.59 million. The stock has a 50 day moving average price of $3.44 and a 200-day moving average price of $2.88.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its quarterly earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.01). The firm had revenue of $2.66 million during the quarter, compared to analyst estimates of $2.63 million. On average, equities research analysts predict that AcelRx Pharmaceuticals, Inc. will post ($1.13) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “AcelRx Pharmaceuticals, Inc. (ACRX) Insider Lawrence G. Hamel Sells 10,161 Shares” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/03/acelrx-pharmaceuticals-inc-acrx-insider-lawrence-g-hamel-sells-10161-shares.html.

Several brokerages recently commented on ACRX. Jefferies Group LLC reissued a “buy” rating and issued a $7.00 price target on shares of AcelRx Pharmaceuticals in a report on Friday, July 14th. Royal Bank Of Canada set a $6.00 price objective on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 25th. Roth Capital reaffirmed a “buy” rating and set a $12.50 price objective on shares of AcelRx Pharmaceuticals in a report on Thursday, August 10th. Stifel Nicolaus raised shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of AcelRx Pharmaceuticals in a research report on Friday, August 4th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.93.

A number of hedge funds and other institutional investors have recently modified their holdings of ACRX. Goldman Sachs Group Inc. purchased a new position in AcelRx Pharmaceuticals during the 2nd quarter valued at about $530,000. WealthTrust Axiom LLC raised its position in AcelRx Pharmaceuticals by 50.0% during the second quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock worth $451,000 after acquiring an additional 70,000 shares during the last quarter. LMR Partners LLP acquired a new position in AcelRx Pharmaceuticals during the second quarter worth about $319,000. Virtu KCG Holdings LLC raised its position in AcelRx Pharmaceuticals by 600.9% during the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after acquiring an additional 101,742 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in AcelRx Pharmaceuticals by 6.6% during the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock worth $355,000 after acquiring an additional 6,942 shares during the last quarter. 23.32% of the stock is currently owned by hedge funds and other institutional investors.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.